Search results
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies. Jan. 26, 2022 | 4 min read. BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced that Steven Rowe, MD, will be its next chief scientific officer.
- The Trouble with Mucus
- 'The Clock Was Always ticking'
- A New Kind of Research Center
- 'One of The Most Remarkable Stories in Modern Medicine'
- Toward Protein-Based Treatment
- 'Very High-Risk'
- Groundbreaking Trials
- Beyond Gating Mutations
- The Triple Combo
- The Readthrough Breakthrough
- GeneratedCaptionsTabForHeroSec
Unless you have a cold, you probably don’t give mucus a second thought. But people with cystic fibrosis can often think of little else. Thick, sticky mucus coats their airways and clogs their lungs, making breathing a chore and infections a constant threat. Salty sweat is another symptom of the same root problem: one of the body’s key hydration reg...
By the early 1990s, despite new, more powerful antibiotics and the use of transplants to replace failing lungs, the average lifespan for a young adult still hovered around age 20. In those years, Steven Rowe, M.D., was a teenage counselor at a camp for children with special medical needs. He got to know “the trials and lack of effective treatments”...
Survival rates have been climbing steadily in cystic fibrosis for decades. Image courtesy Cystic Fibrosis Foundation.When he came to UAB for his medical residency in 1998, Rowe was determined to find treatments that could put time back on that clock. He joined internationally recognized scientists such as Eric Sorscher, Ph.D., and J.P. Clancy, M.D....
“This is one of the most remarkable stories in modern medicine,” says Rowe, professor in the Division of Pulmonary, Allergy and Critical Medicine in the UAB School of Medicine and Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Medical Research at UAB. In CF, genetic testing is now almost universal and mutation-based drug prescribing is sta...
Fixing a protein, unlike fixing a gene, can mean correcting a whole series of errors. The CFTR protein is a gatekeeper. Its station is in the cell membrane, where it allows a variety of substances, including chloride, bicarbonate and ultimately water, to pass in and out of the cell, and acts as a “master regulator of hydration status,” says George ...
This graphic from the Cystic Fibrosis Foundation illustrates normal CFTR functioning (far left) and the different types of mutation classes in cystic fibrosis. Image courtesy Cystic Fibrosis Foundation.The end result is generally the same: dehydrated airways and deranged mucus. But the specific cause in any individual case goes back to the mutation...
And how. When pharmaceutical company Vertex found promising drug candidates, tests developed in Rowe’s lab helped home in on the compounds most likely to improve CFTR protein function. UAB patients were some of the earliest enrollees in the groundbreaking trials of Vertex’s drug ivacaftor, the first protein-focused treatment for cystic fibrosis, wh...
But ivacaftor was always only the tip of the iceberg. A mere 4-6 percent of CF patients have the “gating” mutations that ivacaftor targets, in which CFTR channels cannot open. For the vast majority of patients, the problem is misfolded proteins. Still, the success of ivacaftor “brought a lot of others into the field,” Rowe says. Correctors, a new c...
The next step is the triple combination. Rowe is now co-leading large studies of drugs that combine two correctors plus ivacaftor, to bring even more channels to the membrane. Results from phase 2 trials, reported in October in the New England Journal of Medicine, have been just as impressive as the original ivacaftor studies, he says, including “m...
That’s why patients with nonsense mutations usually have a severe form of the disease, explains David Bedwell, Ph.D., associate director of the UAB Gregory Fleming James Cystic Fibrosis Research Center and chair of the Department of Biochemistry and Molecular Genetics in the UAB School of Medicine. In 1996, Bedwell and colleagues Marybeth Howard, P...
Steven Rowe is the director of the UAB Gregory Fleming James Cystic Fibrosis Research Center, where he leads a team of scientists who have made breakthroughs in treating the genetic disease. Learn how they discovered and developed drugs that target the defective CFTR protein, and how they apply their findings to other lung diseases.
Jan 26, 2022 · Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies. Steven Rowe, MD (Photo: Business Wire) January 26,...
Jan 31, 2022 · The Cystic Fibrosis Foundation (CFF) has appointed Steven Rowe, MD, from the University of Alabama at Birmingham, as its new chief scientific officer. Rowe is a pioneer in CF research and personalized medicine, and will oversee the foundation's basic science, academic research, and venture philanthropy programs.
- Science Writer
People also ask
Does Dr Steven Rowe provide telehealth services?
Who is Steven Rowe?
Is Steve Rowe a doctor?
Who is Marks & Spencer chief executive Steve Rowe?
Steven Rowe, MD. EXECUTIVE VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER, CYSTIC FIBROSIS FOUNDATION. Bethesda, Maryland, United States. Steven M. Rowe, MD, has served as the executive vice president and chief scientific officer of the Cystic Fibrosis Foundation since April 2022.
Mar 10, 2022 · M&S boss Steve Rowe to step down after close to 40 years with retailer. Rowe to be replaced by head of food business Stuart Machin, with Katie Bickerstaffe as co-chief executive. Sarah Butler....
Jul 3, 2023 · July 3, 2023. Steven Rowe, M.D., Ph.D., is Professor and Chief of the Molecular Imaging and Therapeutics Division in the UNC School of Medicine Department of Radiology. Dr. Rowe received his medical degree and Ph.D. in chemistry from the University of Michigan. He completed residencies in radiology and nuclear medicine at Johns Hopkins ...
